Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesMedicenna Therapeutics Corp

Medicenna Therapeutics Corp

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.435 CAD 0.02 ( 4.82%)
Last update at 2026-11-04T20:00:00Z
VOLUME
11126
Market Cap
49.22M

Momentum Score

…

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a tumor-targeting and activatable masked anti-PD-1-IL-2 BiSKITTM for cancer; and MDNA132, an IL-13 Superkine for various tumors. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.42
Low
0.45
High
52 Week Price Range
0.59
Low
1.97
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Medicenna Therapeutics is a clinical-stage biotech developing engineered cytokine therapies for cancer and inflammatory diseases, including an IL-2–based program intended to boost anti-tumor immune cells with less toxicity. Long-term growth may be driven by clinical advancement of its platform, collaborations, and successful combination use with checkpoint inhibitors.

Key risks include clinical and regulatory failure, absence of approved products requiring further financing that could dilute shareholders, and intense competition in immuno-oncology that investors should monitor.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.41
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-109.78%
Net Debt
-16.98M
ROCE
-54.41%
Diluted EPS TTM
-0.15

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Income before tax -13.03M -25.47M -10.05M -22.58M -17.29M
Net income -11.80M -25.47M -10.05M -22.65M -17.39M
Selling general administrative 5.91M 7.87M 6.99M 7.72M 6.49M
Selling and marketing expenses - 0.01M - - -
Gross profit -0.06M -0.01M - - -
Reconciled depreciation 0.05M 0.00M 0.00M 0.04M 0.04M
Ebit -13.03M -18.68M -16.30M -22.30M -17.19M
Ebitda -12.97M -18.67M -16.30M -22.26M -17.15M
Depreciation and amortization 0.06M 0.01M - 0.04M 0.04M
Operating income -21.63M -19.66M -16.30M -22.30M -17.19M
Other operating expenses 21.63M 19.66M - 22.47M 17.39M
Interest expense - - - 0.07M 0.00M
Interest income 8.60M 1.20M 6.25M 0.07M 0.11M
Net interest income 1.35M 1.20M 0.91M 0.07M 0.31M
Income tax expense -1.23M - - 0.07M 0.10M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 21.58M 19.66M 16.30M 22.47M 17.39M
Cost of revenue 0.06M 0.01M - - -
Total other income expense net 8.60M -5.80M 5.34M -0.28M -0.10M
Net income from continuing ops -11.80M -25.47M -10.05M -22.58M -17.29M
Net income applicable to common shares -11.80M -25.47M -10.05M -22.58M -17.29M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Total assets 28.38M 19.13M 36.45M 23.46M 42.25M
Intangible assets 0.05M 0.06M 0.06M 0.07M 0.07M
Other current assets - 0.93M - 1.55M -
Total liab 9.29M 13.94M 6.96M 2.62M 4.11M
Total stockholder equity 19.09M 5.19M 29.49M 20.84M 38.15M
Other current liab - 0.79M 3.16M 0.95M 1.83M
Common stock 116.30M 100.92M 100.92M 83.67M 79.59M
Capital stock 116.30M 100.92M 100.92M 83.67M 79.59M
Retained earnings -118.25M -106.45M -80.98M -70.93M -48.36M
Other assets - 0.00M - - -
Cash 24.84M 16.98M 33.60M 20.54M 30.38M
Cash and equivalents 24.84M - 33.60M 20.54M 30.38M
Total current liabilities 4.43M 2.86M 6.96M 2.62M 4.11M
Net debt - -16.98M - -20.54M -30.34M
Short term debt 0.00M - 0.00M 0.00M 0.03M
Short long term debt total - - - - 0.03M
Other stockholder equity 0.00M 10.70M 0.06M 7.93M 6.68M
Property plant equipment 0.16M - - 0.00M 0.03M
Total current assets 28.17M 19.08M 36.38M 23.39M 42.15M
Net tangible assets - - 29.43M 20.77M 38.07M
Short term investments - - - 0.00M 10.01M
Net receivables - 1.16M 0.85M 1.31M 0.41M
Accounts payable 2.70M 2.07M 1.62M 1.67M 2.25M
Accumulated other comprehensive income - 0.02M - 0.17M 0.23M
Non currrent assets other - -0.00M - - -
Non current assets total 0.21M 0.06M 0.06M 0.07M 0.10M
Capital lease obligations 0.17M - - 0.00M 0.03M
Long term debt total 0.12M - 0.00M 0.00M 0.00M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Investments -0.03M 0.00M 0.00M 10.05M 5.01M
Change to liabilities - - 1.18M -1.45M 2.29M
Total cashflows from investing activities -0.03M - 0.00M 10.05M 5.01M
Net borrowings -0.02M 0.00M - -0.04M -0.04M
Total cash from financing activities 23.49M 0.00M 24.76M 3.88M 18.26M
Net income -11.80M -25.47M -10.05M -22.58M -17.29M
Change in cash 7.86M -16.61M 13.06M -9.84M 7.68M
Begin period cash flow 16.98M 33.60M 20.54M 30.38M 22.70M
End period cash flow 24.84M 16.98M 33.60M 20.54M 30.38M
Total cash from operating activities -16.49M -16.26M -12.66M -23.58M -15.31M
Issuance of capital stock 19.71M 0.00M 24.76M 3.51M 11.41M
Depreciation 0.05M 0.00M 0.00M 0.04M 0.04M
Other cashflows from investing activities - - 0.00M 10.05M 5.01M
Change to account receivables -0.21M 1.68M 1.23M -0.39M -1.61M
Sale purchase of stock 23.51M 0.00M 24.76M 3.92M 18.30M
Other cashflows from financing activities 3.80M - - 0.41M 6.88M
Change to netincome - - -5.02M 0.80M 1.26M
Capital expenditures 0.03M 0.00M 0.00M 0.00M 0.00M
Change in working capital 1.31M 0.74M 2.41M -1.84M 0.68M
Stock based compensation 2.21M 1.21M 1.37M 1.42M 1.01M
Other non cash items -8.27M 7.25M -0.97M -0.62M 0.25M
Free cash flow -16.52M -16.26M -12.66M -23.58M -15.31M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
MDNA
Medicenna Therapeutics Corp		 0.02
4.82%		 0.43 - 232.56 - 8.06 -6.11
EPRX
Eupraxia Pharmaceuticals Inc		 -0.17
1.76%		 9.48 - - - 8.45 -3.88
FRX
Fennec Pharmaceuticals Inc		 0.20
1.35%		 14.99 - 21.01 6.95 6.35 20.27
MSCL
Satellos Bioscience Inc.		 -
-%		 9.00 - - - 5.85 6.47
HBP
Helix BioPharma Corp.		 -0.10
9.80%		 0.92 - 3.87 4263.36 9.74 -6.36

Profile*

Medicenna Therapeutics Corp

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a tumor-targeting and activatable masked anti-PD-1-IL-2 BiSKITTM for cancer; and MDNA132, an IL-13 Superkine for various tumors. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.

2 Bloor Street West, Toronto, ON, Canada, M4W 3E2

416 648 5555

https://www.medicenna.com

18

Name Title Year Born
Dr. Fahar Merchant Ph.D. Founder, Chairman, Pres & CEO 1957
Ms. Rosemina Merchant B.Sc., M.E.Sc Founder, Chief Devel. Officer & Director 1957
Ms. Elizabeth Williams C.A., CPA, CA, CPA CFO & Corp. Sec. 1978
Dr. Martin Bexon M.D., MBBS Acting Chief Medical Officer & Head of Clinical Devel. NA
Dr. Samuel R. Denmeade M.D. Scientific Advisor NA
Dr. Fahar Merchant Ph.D. Founder, Chairman, President & CEO 1957
Ms. Rosemina Merchant B.Sc., M.E.Sc Founder & Chief Development Officer 1957
Mr. David Hyman CA, CBV Chief Financial Officer 1973
Dr. Nageatte Ibrahim M.D. Chief Medical Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…